// App-Quantinova.ai

POS0696 (2021) : SAFETY AND EFFICACY OF BELIMUMAB IN OLDER ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF AN INTEGRATED ANALYSIS

Researchers

Presenter

  • D. Dcruz

Principal Investigators

  • G. Eriksson

  • Y. Green

  • A. Hammer

  • B. Ji

  • P. Meizlik

  • D. Roth

Medical Centers

  • Guy’s Hospital, Louise Coote Lupus Unit, London, United Kingdom

  • GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, United States of America

  • GlaxoSmithKline, Clinical Development, Brentford, Middlesex, United Kingdom

  • GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, United States of America

  • GlaxoSmithKline, Clinical Development, Brentford, Middlesex, United Kingdom

  • GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, United States of America

  • GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, United States of America

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • Belimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • GlaxoSmithKline (GSK)

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved